GlassScriptPhysician profile
Malia Keen
NPI 1780294298
$19,053.55
in general payments reported to CMS, 2019-2025
73 companies · $4,372 in 2025
The $4,372 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,261 · 2022: $3,434 · 2023: $4,246 · 2024: $4,740 · 2025: $4,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Long Term Medical Supply Or Device Loan: $1,216 · Education: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,777.37 |
| Long Term Medical Supply Or Device Loan | $1,215.73 |
| Education | $364.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,552.68 | 2021-2025 | |
| Janssen Biotech, INC. | $1,773.40 | 2021-2025 | Darzalex, Rybrevant, Tecvayli |
| Merck Sharp & Dohme LLC | $1,196.12 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $1,076.58 | 2021-2025 | Lynparza, Enhertu, Imfinzi |
| Celgene Corporation | $876.44 | 2021-2025 | Pomalyst, Reblozyl, Opdualag |
| Pfizer INC. | $818.75 | 2021-2025 | |
| Genzyme Corporation | $645.79 | 2021-2025 | |
| Seagen INC. | $538.96 | 2021-2025 | Tivdak, Padcev, Adcetris |
| Bayer Healthcare Pharmaceuticals INC. | $530.04 | 2021-2025 | |
| Abbvie INC. | $488.29 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $487.77 | 2021-2025 | Opdivo, Opdualag |
| Glaxosmithkline, LLC. | $473.87 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Lilly USA, LLC | $449.88 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Eisai INC. | $432.10 | 2021-2025 | |
| Astellas Pharma US INC | $419.50 | 2021-2025 | Xtandi, Vyloy, Padcev |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $411.36 | 2021-2025 | Jakafi, Niktimvo, Monjuvi |
| Daiichi Sankyo INC. | $379.46 | 2021-2025 | Enhertu, Datroway |
| Beigene USA, INC. | $334.13 | 2022-2024 | Brukinsa |
| Amgen INC. | $332.13 | 2021-2023 | Xgeva, Nplate, Vectibix |
| Ipsen Biopharmaceuticals, INC | $326.78 | 2021-2025 | Onivyde, Somatuline Depot, Tazverik |
| Pharmacyclics LLC, An Abbvie Company | $321.63 | 2022-2023 | Imbruvica, Epkinly |
| Jazz Pharmaceuticals INC. | $292.54 | 2021-2025 | |
| Emd Serono, INC. | $275.84 | 2023-2025 | Bavencio |
| Takeda Pharmaceuticals U.S.A., INC. | $263.88 | 2023-2025 | Fruzaqla, Iclusig, Ninlaro |
| Regeneron Healthcare Solutions, INC. | $263.10 | 2021-2024 | Libtayo |
| Array Biopharma INC | $250.72 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Sobi, INC | $240.26 | 2022-2025 | |
| Gilead Sciences, INC. | $216.18 | 2022-2025 | Trodelvy |
| Stemline Therapeutics INC. | $197.05 | 2023-2025 | Orserdu |
| Pharmacosmos Therapeutics INC. | $179.14 | 2023-2024 | Monoferric, Cosela |
| Servier Pharmaceuticals LLC | $161.60 | 2023-2025 | |
| Beone Medicines USA, INC. | $111.36 | 2025 | Brukinsa |
| Pharmaessentia USA Corporation | $95.56 | 2024-2025 | Besremi |
| Sanofi-Aventis U.S. LLC | $91.00 | 2023 | |
| Karyopharm Therapeutics INC. | $82.64 | 2021-2025 | Xpovio |
| Puma Biotechnology, INC. | $82.07 | 2022-2025 | |
| Taiho Oncology, INC. | $77.79 | 2021-2025 | |
| Myovant Sciences INC. | $70.32 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $69.00 | 2021-2024 | |
| Foundation Medicine, INC. | $68.05 | 2021-2023 | |
| Rigel Pharmaceuticals, INC. | $65.89 | 2024-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Tersera Therapeutics LLC | $65.53 | 2025 | Zoladex |
| Alexion Pharmaceuticals, INC. | $58.10 | 2024-2025 | Ultomiris |
| Genentech USA, INC. | $57.97 | 2022-2025 | Tecentriq |
| Legend Biotech USA INC. | $57.12 | 2024-2025 | Carvykti |
| Myriad Genetic Laboratories, INC. | $52.73 | 2021-2022 | |
| Geron Corporation | $47.57 | 2024-2025 | Rytelo |
| Biocon Biologics INC | $45.84 | 2024 | Fulphila, Ogivri |
| Morphosys, US INC. | $45.68 | 2021-2022 | |
| Eusa Pharma (US) LLC | $43.92 | 2021 | |
| Mirati Therapeutics, INC. | $43.81 | 2024 | Krazati |
| Alnylam Pharmaceuticals INC. | $41.96 | 2023 | Givlaari |
| Exelixis INC. | $40.78 | 2024-2025 | Cabometyx |
| Adc Therapeutics America, INC. | $40.28 | 2024-2025 | |
| Amag Pharmaceuticals, INC. | $37.71 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $29.35 | 2025 | Provenge |
| Dova Pharmaceuticals | $27.20 | 2021 | |
| Blueprint Medicines Corporation | $26.50 | 2022 | |
| Adaptive Biotechnologies Corporation | $26.46 | 2022 | |
| Azurity Pharmaceuticals, INC. | $25.41 | 2025 | Danziten |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.92 | 2025 | |
| Deciphera Pharmaceuticals INC. | $22.36 | 2022 | |
| G1 Therapeutics, INC. | $22.19 | 2023 | Cosela |
| Recordati_rare_diseases_inc. | $21.48 | 2025 | Enjaymo |
| Sumitomo Pharma America, INC. | $20.69 | 2025 | Orgovyx |
| Novocure INC. | $18.22 | 2025 | Optune Lua (Novottf-200t) |
| Csl Behring | $16.69 | 2021 | |
| Clovis Oncology, INC. | $16.31 | 2021 | |
| Sun Pharmaceutical Industries INC. | $15.48 | 2022 | |
| Agios Pharmaceuticals, INC. | $15.00 | 2024 | |
| Teleflex LLC | $11.34 | 2021 | |
| Pharmaand Gmbh | $10.07 | 2025 | Rubraca |
| Janssen Pharmaceuticals, INC | $5.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malia Keen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.